secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001564590-22-011122
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio reports FY2021 net loss $70.8M; GPH101 first patient dosing delayed to H2 2022
--------------------------------------------------------------------------------

- Cash, equivalents, restricted cash $378.7M as of Dec 31, 2021; runway into Q4 2024.
- FY2021 net loss $70.8M ($2.45/share); Q4 net loss $18.9M ($0.35/share).
- GPH101 Phase 1/2 CEDAR trial: first patient dosing now H2 2022 (COVID-19 impact); initial data 2023.
- New programs: GPH102 for beta-thalassemia (IND mid-2024) and early AAT deficiency program.
- Appointed Alethia Young as CFO, Christine Garrett as Chief of Staff/SVP Ops; promoted Julia Tran to CPO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022011122/0001564590-22-011122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000156459022011122/grph-8k_20220321.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-011122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer